Skip to main content
OpenTrials
Completed

NCT Number: NCT00312195

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10 and 20) in comparison to matching placebo transdermal system in subjects with chronic nonmalignant pain syndromes currently controlled by oral opioids. The double-blind treatment intervention duration is 2 weeks during which time supplemental analgesic medication (acetaminophen) will be provided to all subjects in addition to study drug.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Non-malignant Pain Chronic Pain Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Whiteabbey Health Centre, Newtownabbey, Belfast, United Kingdom

Loading trial locations.

About this study

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 2 month's history of nonmalignant pain, currently in stable pain control on opioid therapy.
  • Good, very good or excellent pain control on current opioid therapy.
  • Willing and able to use a telephone interactive voice response service.

Exclusion criteria

  • Currently receiving daily morphine or oxycodone monotherapy.
  • Scheduled for surgery of the disease site (eg, major joint replacement surgery), or any other major surgery, which would fall within the study period.

Other protocol-specific exclusion/inclusion criteria may apply.

Treatment and study plan

Buprenorphine transdermal patch

Drug

Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.

Other names: Butrans™

Placebo to match BTDS

Drug

Placebo to match buprenorphine transdermal patch applied for 7-day wear.

Primary outcomes

  1. The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase.

    Time frame: Double-blind phase (14 days)

    Ineffective treatment was defined as:

    • Subject took >1 gram of acetaminophen in a 24-hour period, or
    • Subject required a change in transdermal patch (TDS) dose, or
    • Subject had difficulty in keeping the TDS on, or
    • Subject discontinued due to ineffective treatment (but did not meet any of the above criteria).

    Note: some subjects may have had multiple reasons for ineffective treatment and are counted under each category. Therefore the sum of subjects across all criteria for ineffective treatment is greater than the total number of subjects with ineffective treatment.

Secondary outcomes

  1. Time (Days) From the Initial Dose of Study Drug in the Double-blind Evaluation Phase to Ineffective Treatment

    Time frame: 14 days

    The time of ineffective treatment was calculated as the earliest of the following:

    • The date the subject first took >1 gram of acetaminophen,
    • The visit date when ineffective treatment was first determined, or
    • The date the last patch was removed.

  2. The Number of Subjects Who Had Ineffective Treatment or Who Discontinued Due to Reasons Other Than Ineffective Treatment in the Double-blind Phase

    Time frame: 14 days

    Note: The total numbers of "Subjects w/ineffective treatment or who discont'd" for placebo and BTDS are 1 less because there were reasons other than lack of efficacy that made up this total: adverse event, death, lost to follow- up, protocol violation, and other. Example for placebo 89+5=94; however, 93 is indicated for the total because there is 1 subject in the placebo group who was counted under ineffective treatment and discontinued due to reasons other than lack of efficacy. The same is true for 1 subject in BTDS.

  3. The Amount of Rescue Medication Used for Pain (Average Daily Number of Acetaminophen Tablets).

    Time frame: 14 days

    The average daily acetaminophen (Panadol) use (1 tablet = 500 mg) during the double-blind phase was compared between the treatment groups using ANCOVA methodology with terms for country and treatment. The average escape medication used in the last 4 days prior to randomization was included as a covariate.

Sponsors and collaborators

Lead sponsor

Purdue Pharma LP

Industry

Collaborators

  • Napp Pharmaceuticals Limited

Registry information

Official study title

An Open-label Run-in, Followed by a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Show the Effectiveness of Buprenorphine Transdermal System in Management of Patients With Chronic Nonmalignant Pain Syndromes

Important dates

Study start
2001
Primary completion
2001
Study completion
2001
First posted
Apr 7, 2006
Registry last updated
Sep 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.